Skip to main content
. 2015 May 13;107(7):djv135. doi: 10.1093/jnci/djv135

Figure 7.

Figure 7.

Exosomic miR-155 and cisplatin resistance in neuroblastoma (NBL) cells. A) Growth curves of SK-N-BE(2) cells not Dotap-treated and not treated with cisplatin (control group), or treated with Dotap-Scrambled and cisplatin (scr+cis group), or treated with Dotap-miR-155 and cisplatin (miR-155+cis group). B) Same experiment described in (A) but in CHLA-255 NBL cells. C) Cell count for SK-N-BE(2) cells pretransfected with a plasmid expressing the whole TERF1 gene (WT group) or just TERF1 coding sequence (no 3’-UTR group) and treated with cisplatin and Dotap-miR-155 for the indicated time periods. D) Immunoblotting for TERF1 in the same groups described in (C). Data are presented as mean ± SD of experiments conducted in triplicate. *P = .01, **P = .003, ***P = .001, ****P < .001, Student’s t test, two-sided.